ConductScience.org, home

Comparison · NCT03443063-55c26991

Lemborexant: Severe Renal Impairment vs Lemborexant: Normal Renal Function: Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Parameter Values

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Lemborexant: Severe Renal Impairment vs Lemborexant: Normal Renal Function: Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Parameter Values. Trial comparisons, record NCT03443063-55c26991. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03443063-55c26991

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.324wilson
Risk in group 2000.324wilson
Risk difference, group 1 minus group 20-0.3240.324newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treatfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Lemborexant: Severe Renal ImpairmentParticipants with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m\^2 and not on dialysis) received a single dose of 10 mg lemborexant (oral tablet) in the morning after an overnight fast.08OG000
Group 2Lemborexant: Normal Renal Function
Participants with normal renal function (eGFR \>=90 mL/min/1.73 m\^2) demographically matched to participants with severe renal impairment (matched according to age, race, sex, and BMI) received a single dose of 10 mg lemborexant (oral tablet) on Day 1 in the morning after an overnight fast.
08OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Parameter Values
Description
Time frame
Up to Day 11
Population
The safety analysis set was the group of participants who were dosed with the test drug and had at least one postdose safety assessment.

Source ClinicalTrials.gov

Trial

Title
Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment
NCT number
NCT03443063
Phases
PHASE1
Conditions
Renal Impairment
Interventions
Lemborexant
Lead sponsor
Eisai Inc.
Results first posted
2020-01-18

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03443063-55c26991